Novo Holdings, the parent company of Danish pharma giant Novo Nordisk, agreed to buy New Jersey-based contract manufacturer Catalent for around $16.5 billion in cash. Why it matters: This deal is about boosting production of Wegovy, the anti-obesity drug whose demand has far outpaced supply. Details: The $63.50 per share purchase price represents a 16.5% premium to Friday's closing price, and a 39.1% premium to trading before Catalent's board announced a strategic review in late August. Go deeper, per the WSJ : "The popularity of Wegovy has seen the company restrict supply while it scrambles to increase stocks. In recent months, it has outlined plans to invest more than $6 billion to increase capacity. Last month, Novo Nordisk began gradually increasing supplies of lower-dose strengths, having limited supply in the U.S. since May to safeguard access for current patients."